Hesperadin, 98%, an ATP-competitive inhibitor of aurora B kinase

Name: Hesperadin, 98%, an ATP-competitive inhibitor of aurora B kinase | 422513-13-1
Brand: J&K Chemical
SKU: JK1563114_5_MG
Price: 102.6 USD
Availability: OutOfStock

Cat. No JK1563114_5_MG

Vendor: J&K Chemical

Product Information

Product Name

Hesperadin, 98%, an ATP-competitive inhibitor of aurora B kinase

Brand Name

J&K

Product Number

1563114

CAS

422513-13-1

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

135421442

IUPAC Name

N-2-hydroxy-3-C-phenyl-N-4-(piperidin-1-ylmethyl)phenylcarbonimidoyl-1H-indol-5-ylethanesulfonamide

InChI Key

HYHIYZMIFPJROG-UHFFFAOYSA-N

SMILES

CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=C2C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5)O

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2024-03-15

DOI: 10.1016/j.ejmech.2024.116255

Development of Selective Pyrido[2,3- d ]pyrimidin-7(8 H )-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2024-02-29

DOI: 10.1021/acs.jmedchem.3c02217

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

Publication Name: Cancer Letters

Publication Date: 2023-08-01

DOI: 10.1016/j.canlet.2023.216284

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

Publication Name: Journal of experimental & clinical cancer research : CR

Publication Date: 2023-04-25

DOI: 10.1186/s13046-023-02667-4

Hesperadin, 98%, an ATP-competitive inhibitor of aurora B kinase

Product Information

General Information

Safety Information

References Data Source From Pubchem

Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells

Development of Selective Pyrido[2,3- d ]pyrimidin-7(8 H )-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma